Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model

Current Neurovascular Research

Volumn 9, Issue 3, 2012, Pages 207-213

  Kandadai, Madhuvanthi A ^a   Meunier, Jason ^a   Lindsell, Christopher J ^a   Shaw, George J ^a,b   Elkind, Mitchell S V ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Acute Ischemic Stroke; Human blood clot model; Lovastatin; Neuroprotection; rt PA; Thrombolysis

Indexed keywords

ALCOHOL; ALTEPLASE; DRUG METABOLITE; FRESH FROZEN PLASMA; LOVASTATIN HYDROXY ACID; MEVINOLIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HEMOSTASIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MICROSCOPY; MODEL; PRIORITY JOURNAL;

EID: 84865230660     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720212801619054     Document Type: Article

References (68)

1. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35:2708-11. (Pubitemid 39458376)
2. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol 2005; 27:1401-9.
3. Liao J, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89-118. (Pubitemid 40261799)
4. Suzuki N, Imai A. HMG-CoA reductase inhibitor lovastatin upregulates plasminogen activator production through RhoAsignaling in peritoneal cell line Met5A. Gynecol Surg 2010;7:189-93.
5. B.A. Hamelin, Turgeon J. Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19(1):26-37. (Pubitemid 28094090)
6. Sacks FM, Pfeffer MA, Moye LA, et al. The Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335(14):1001-9. (Pubitemid 26338729)
7. Stalenhoef AF. Scandinavian simvastatin study (4S). Lancet 1994; 344:8939-40.
8. Chróinin DN, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke the north dublin population stroke study. Stroke 2011; 42:1021-9.
9. Elkind M, Flint A, Sciacca R, et al. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005; 65:253-8. (Pubitemid 41022370)
10. Schwartz GG, Chaitman BR, Goldberger JJ, et al. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J 2011; 161(5):993-9.
11. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493):1267-78.
12. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006; 355(6):549-59.
13. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998; 279(20):1615-22. (Pubitemid 28248586)
14. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203(2):325-30.
15. Prinz V, Endres M. Statins and stroke: Prevention and beyond. Curr Opin Neurol 2011; 24(1):75-80.
16. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005; 25(9):1093-110. (Pubitemid 41710736)
17. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(23 suppl 1):III-39-43. (Pubitemid 38786442)
18. Lahera V, Goicoechea M, de Vinuesa SG, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007; 14(2):243-8. (Pubitemid 46043919)
19. Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012; 43(1):147-54.
20. Ford AL, An H, D'Angelo G, et al. Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke 2011; 42(5):1307-13.
21. Desai H, Aronow WS, Ahn C, et al. Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Arch Gerontol Geriatrics 2010; 51(2):149-51.
22. Ishida K, Geshi T, Nakano A, et al. Beneficial effects of statin treatment on coronary microvascular dysfunction and left ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 2012; 155(3):442-7.
23. Kitahara M, Kanaki T, Ishii I, et al. Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin. Brit J Pharmacol 2010; 159(7):1418-28.
24. Antoniades C, Demosthenous M, Reilly S, et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery: Effects of short-term pre-operative statin treatment. J Am Coll Cardiol 2012; 59(1):60-70.
25. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93(10):948-56. (Pubitemid 37441285)
26. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25(2):287-94. (Pubitemid 40189147)
27. Pastuszczak M, Kotlarz A, Mostowik M, et al. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res 2010; 125(5):382-6.
28. Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103(18):2248-53. (Pubitemid 32433713)
29. Elkind MSV. Statins as acute-stroke treatment. Int J Stroke 2006; 1(4):224-5. (Pubitemid 44541736)
30. Li B, Mahmood A, Lu D, et al. Simvastatin attenuates microglia, astrocyte activation and decreases IL-1β level following traumatic brain injury. Neurosurgery 2009; 65(1):179-86.
31. Yang D, Knight RA, Han Y, et al. Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: Magnetic resonance imaging and histological study: Laboratory investigation. J Neurosurg 2011; 114(4):1135-42.
32. Guluma KZ, Lapchak PA. Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. Brain Res 2010; 1354:206-16.
33. Lapchak PA, Han MK. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res 2009;1303(0):144-50.
34. Lapchak PA, Han MK. Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res 2010; 1344(0):217-25.
35. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci 1998; 95(15):8880-5. (Pubitemid 28350583)
36. Pahan K, Sheikh FG, Namboodiri AM, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100(11):2671-9. (Pubitemid 28007534)
37. Zhang L, Chopp M, Jia L, et al. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 2009; 29(11):1816-24.
38. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34(2):551-7. (Pubitemid 36206363)
39. Elkind MSV, Sacco RL, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovascular Dis 2009; 28(3):266-75.
40. M. Blanco, F. Nombela, M. Castellanos, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007; 69(9):904-10. (Pubitemid 47329591)
41. Jasińska-Stroschein M, Owczarek J, Wejman I, et al. Novel mechanistic and clinical implications concerning the safety of statin discontinuation. Pharmacol Rep 2011; 63(4):867-79.
42. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000; 152(2):359-66.
43. Essig M, Nguyen G, Priè D, et al. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and rho proteins. Circ Res 1998; 83(7):683-90. (Pubitemid 28462781)
44. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31:2442-9.
45. Ding G, Jiang Q, Li L, et al. MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin. J Neurol Sci 2006; 246(1-2):139-47. (Pubitemid 43815356)
46. Zhang L, Zhang ZG, Ding GL, et al. Multitargeted effects of statinenhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005; 112(22):3486-94. (Pubitemid 43739565)
47. Jaffe GJ, Green GD, Abrams GW. Stability of recombinant tissue plasminogen activator. Am J Ophthalmol 1989; 108(1):90-1. (Pubitemid 19177069)
48. Shaw GJ, Sperling M, Meunier JM. Long-term stability of recombinant tissue plasminogen activator at-80°C. BMC Res Notes 2009; 2:117.
49. Collen D, Bounameaux H, Cock FD, et al. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73(3):511-7. (Pubitemid 16133030)
50. McNicol G, Fletcher A, Alkjaersig N, Sherry S. The absorption, distribution, and excretion of epsilon-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59:15-24.
51. Nielsen VG, Cankovic L, Steenwyk BL. Epsilon-aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered? Blood Coagul Fibrinol 2007; 18:35-9. (Pubitemid 46006271)
52. Green JA, Spiess BD. Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest. Anesth Clin N Am 2003; 21:527-51. (Pubitemid 37169543)
53. Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107(1):136-40. (Pubitemid 43939039)
54. Krishnamurti C, Vukelja SJ, Alving BM. Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis. Thromb Res 1994; 73(6):419-30. (Pubitemid 24094574)
55. Adelman B, Rizk A, Hanners E. Plasminogen interactions with platelets in plasma. Blood 1988; 72(5):1530-5.
56. Winter P, Shukla H, Caruthers S, et al. Molecular imaging of human thrombus with computed tomography. Acad Radiol 2005; 12 Suppl 1:S9-13. (Pubitemid 41150886)
57. Yu X, Song SK, Chen J, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Mag Res Med 2000; 44:867-72.
58. Marinkovic SV, Milisavljevic MM, Kovacevic MS, et al. Perforating branches of the middle cerebral artery. Microanatomy and clinical significance of their intracerebral segments. Stroke 1985; 16(6):1022-9. (Pubitemid 16211513)
59. Tao X, Yu XJ, Bhattarai B, et al. Microsurgical anatomy of the anterior communicating artery complex in adult chinese heads. Surg Neurol 2006; 65(2):155-61. (Pubitemid 43112153)
60. Francis C, Totterman S. Magnetic resonance imaging of deep vein thrombi correlates with response to thrombolytic therapy. J Thromb Haemost 1995; 73:385-91.
61. Loren M, Garcia Frade LJ, Torrado MC, et al. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res 1989; 56(1):67-75.
62. Shaw GJ, Meunier JM, Lindsell CJ, et al. Tissue plasminogen activator concentration dependence of 120 kHz ultrasoundenhanced thrombolysis. Ultrasound Med Biol 2008; 34(11):1783-92.
63. Meunier JM, Smith DAB, Holland CK, et al. 120 kHz pulsed ultrasound enhanced thrombolysis with tissue plasminogen activator-loaded echogenic liposomes. J Acous Soc Am 2007b; 122:3052.
64. Shaw GJ, Meunier JM, Lindsell CJ, et al. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res 2010; 126(4):e305-11.
65. Meunier JM, Holland CK, Porter TM, et al. Combination treatment with rt-PA is more effective than rt-PA alone in an in-vitro human clot model. Curr Neurovasc Res 2011; 8(4):305-12.
66. Meunier JM, Smith DAB, Holland CK, et al. 120 kHz pulsed ultrasound enhanced thrombolysis with tissue plasminogen activator-loaded echogenic liposomes. J Acous Soc Am 2007; 122:3052.
67. Meunier JM, Holland CK, Pancioli AM, et al. Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. Thromb Res 2009; 123(3):528-36.
68. Shaw GJ, Meunier JM, Lindsell CJ, et al. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res 2010; 126(4):305-11.